Symposium Program. 28 August Kindly sponsored by Abbott Fresenius Kabi USA, LLC QualTex Laboratories Roche Terumo BCT - Page 1
|
|
|
- Gertrude Bishop
- 6 years ago
- Views:
Transcription
1 Symposium Program 28 August 2017 Kindly sponsored by Abbott Fresenius Kabi USA, LLC QualTex Laboratories Roche Terumo BCT - Page 1
2 Day I Monday 11 September :00 hrs Session 1: OPENING SESSION Chairperson: Mr B. Block Welcome and Introduction Dr P. Strengers, IPFA (The Netherlands) (10 mins) Presentation by Blood Assurance Blood Assurance representative (USA) (15 mins) Opening - Dr C. Hooper, Centers for Disease Control (USA) (15 mins) Key-Note Lecture Setting the scene Mr P. Robert, Marketing Research Bureau, Inc. (USA) (30 mins) 10:15 hrs COFFEE BREAK 10:45 hrs Session 2: PATIENTS PERSPECTIVE: WHY THE NECESSITY FOR INCREASING THE PLASMA PRODUCTION? Chairperson: Mr M. Skinner Value of immunoglobuline products for GBS / CIDP patients Mr J. Crone, GBS / CIDP Foundation International (USA) (20 mins) Living with von Willebrand disease Ms J. Graham and Mr J. Kocsis (USA) (20 mins) Clinical use of plasma products including impact of new developments in the optimal production and potential use of Plasma-derived medicinal products Dr S. Stowell, Emory University School of Medicine (USA) (20 mins) Panel discussion (30 mins) 12:15 hrs LUNCH Kindly sponsored by Abbott Fresenius Kabi USA, LLC QualTex Laboratories Roche Terumo BCT Page 2
3 13:45 hrs Session 3: STRATEGIC APPROACHES TO THE SECURITY OF THE SUPPLY Chairperson: Dr P. Strengers Ensuring security of the Canadian plasma supply for immune globulin Mr M. Haun, Canadian Blood Services (Canada) (20 mins) Towards a sustainable blood supply in the US - View of different stakeholders; including presentation from RAND - Dr J. Menitove, ACBTSA (USA) (20 mins) Blood Supply Sustainability The next chapter Dr B. Carden, Common Wealth Transfusion Foundation (USA) (20 mins) Panel Discussion (30 mins) 15:15 hrs COFFEE BREAK 15:45 hrs Session 4: PRACTICAL, OPERATIONAL APPROACHES FOR CHANGING A BLOOD CENTER INTO A BLOOD/PLASMA COLLECTION CENTER Chairperson: Ms J. Ficenec Experiences BloodSource Mr R. Van Tuyle (USA) (20 mins) Experiences LifeServe Blood Center Ms S. Sime (USA) (20 mins) Experiences Blood Assurance Mr C. Swafford (USA) (20 mins) Panel discussion (30 mins) 17:15 hrs END OF DAY I 18:45 hrs DEPARTURE FOR SYMPOSIUM RECEPTION AT THE ATLANTA HISTORY CENTER KINDLY OFFERED BY BLOOD ASSURANCE Kindly sponsored by Abbott Fresenius Kabi USA, LLC QualTex Laboratories Roche Terumo BCT Page 3
4 Day II Tuesday 12 September :00 hrs Session 5: MANUFACTURERS SESSION Chairperson: Dr F. Rossi Abbott Be The 1 Global Donor campaign Mr E. Slocum (USA) (20 mins) QualTex Laboratories Infectious disease testing of source plasma donations: The past and the future Dr S. Jones (USA) (20 mins) 10:00 hrs COFFEE BREAK 10:30 hrs Session 6: TTIs AND MICROBIOLOGICAL RISKS Chairperson: Dr R. Perry FDA Transfusion Transmitted Infections Monitoring System (TTIMS) Dr S. Stramer, American Red Cross (USA) (20 mins) Impact of MSM policy changes in multiple countries and planned Canadian studies of individual donor risk assessments Dr M. Germain, Héma-Quebec (Canada) (20 mins) Analysis of US Source Plasma Infectious disease residual risk compared to Recovered Plasma Residual Risk - Dr G. Schreiber, Plasma Protein Therapeutics Association (USA) (20 mins) Panel discussion (30 mins) 12:00 hrs LUNCH Kindly sponsored by Abbott Fresenius Kabi USA, LLC QualTex Laboratories Roche Terumo BCT Page 4
5 13:30 hrs Session 7: REGULATORY CONVERGENCE Chairperson: Ms R. Sylvester US and EU view on GMP inspections - Potential Future Mutual Agreement for Inspections Dr F. Rossi, IPFA (The Netherlands) (20 mins) Regulatory Constraints for Recovered plasma as source for plasma for fractionation Ms S. Conway, Blood Centers of America (USA) (20 mins) Plasma donation in the United States: Scientific Review Dr M. Rosa-Bray, Grifols (USA) (20 mins) Donor safety, including EU requirements volumes, frequency, testing - Dr J. Hughes, BloodSource, Inc. (USA) (20 mins) Panel Discussion (25 mins) 15:15 hrs Session 8: A VIEW ON THE FUTURE Chairperson: Mr R. Van Tuyle Plasma Based Medicines A Distributors Perspective Ms L. Matthews, BioCARE (USA) (20 mins) A view of the Hospital Marketplace Mr W. Woodward, Vizient Inc. (USA) (20 mins) 16:15 hrs CLOSURE 16:30 hrs FAREWELL DRINKS Kindly sponsored by Abbott Fresenius Kabi USA, LLC QualTex Laboratories Roche Terumo BCT Page 5
6 Kindly sponsored by Abbott Fresenius Kabi USA, LLC QualTex Laboratories Roche Terumo BCT Page 6
Workshop Programme. 10 May 2017
Workshop Programme 10 May 2017 Kindly sponsored by Abbott Cerus Corporation DiaSorin S.p.A. GFE Blut Grifols Macopharma Roche Diagnostics Terumo BCT - Page 1 Day I - Tuesday 16 May 2017 08.45 hrs SESSION
IG Production and Safety
IG Production and Safety Platelet Disorder Support Association July 20, 2013 Mary Gustafson, Vice President, PPTA Global Regulatory Policy Presentation Outline Introduction - PPTA Plasma Collection Final
Asia Pacific Economies Drive Quality
Asia Pacific Economies Drive Quality Industry s Response Jerry A Holmberg, Ph.D. Director, Scientific Business Development March 3, 2017 GRP No. DL/TMP/0217/0007 Agenda What is APEC? Why is blood sustainability
Device: Good Manufacturing Practices Manual
Device: Good Manufacturing Practices Manual If searched for a ebook Device: Good Manufacturing Practices Manual in pdf format, then you have come on to loyal site. We present complete variation of this
Bioscience Division sales increase 15% to drive Grifols revenue growth by 11% to Euros 1,062 million
First Quarter 2017 Results Free translation from the original in Spanish Bioscience Division sales increase 15% to drive Grifols revenue growth by 11% to Euros 1,062 million Grifols market positioning
DISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND
REASON FOR CHANGE: Wholesaler s licences are now issued by the Ministry of Health rather than Medsafe; clarify the approval process for the supply of products only to authorised facilities and healthcare
Grifols net profit up by +6.2% to million euros and sales grow by +13.8% in the first quarter of 2015
Grifols net profit up by +6.2% to 128.5 million euros and sales grow by +13.8% in the first quarter of 2015 Income grows by +13.8% (+1.1% constant currency (cc) 1 ) to Euros 908.4 million, driven by sales
Impact of WHO Guidelines on GMP for Blood Establishments
Impact of WHO Guidelines on GMP for Blood Establishments Christian Schärer, Ph.D. Swissmedic, Swiss Agency for Therapeutic Products, Head Inspectorate International Conference of Drug Regulatory Authorities
FDA Perspective on Plasma Quality and GMPs
FDA Perspective on Plasma Quality and GMPs Judy Ellen Ciaraldi Food and Drug Administration Division of Blood Components & Devices/OBRR/CBER IPFA/BCA Global Symposium September 23, 2014 Sacramento, California
Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative
Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative Dr Vadim Sentchouk PHARMLAND LLC Deputy General Director PLASMAPHARM LLC General
Overall progress in the first quarter of 2007
F I R S T Q U A R T E R R E P O R T 2 0 0 7 Overall progress in the first quarter of 2007 Grifols has obtained a turnover of 181.8 million euros in the first quarter of the year, an increase of 20.4% compared
PLASMA DERIVATIVES IN EUROPE AN IPFA PERSPECTIVE R J PERRY - IPFA
PLASMA DERIVATIVES IN EUROPE AN IPFA PERSPECTIVE R J PERRY - IPFA INTERNATIONAL PLASMA FRACTIONATION ASSOCIATION Aligns its ac9vi9es with the needs of all pa9ents dependent on blood and plasma products
Implementing 7 Day Platelet Dating with the Platelet PGD Test
Implementing 7 Day Platelet Dating with the Platelet PGD Test The Verax Biomedical Platelet Pan Genera Detection (PGD ) Test is a rapid, qualitative immunoassay for the detection of aerobic and anaerobic
Supplementary Online Content
Supplementary Online Content Garban F, Guyard A, Labussière H, et al; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the hemostatic
Dr. Anneliese Hilger Chair, Blood Products Working Party (BPWP)
Reference: EMA16006a BY E-MAIL Dr. Peter Bachmann Chair, Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) Email: peter.bachmann@bfarm.de; H-CMDhSecretariat@ema.europa.eu
Stephen Strom (Cell Transplantation and Regenerative Medicine, KI) Stem Cell Therapy of Liver Disease
Final Programme Tuesday 13 th October Location: HERM Seminar Room, NOVUM, 4 th Floor (entrance through HERM) 9.15-9.20 Welcome and Introduction to the Sessions Chair: Hong Qian (HERM, KI) 9.20-10.15 Hong
An overview of the Asia Pacific Blood Network and Overview of the status of plasma fractionation in the region
An overview of the Asia Pacific Blood Network and Overview of the status of plasma fractionation in the region Overview» APBN Membership Vision and mission & strategic objectives Activities Plasma for
Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million
Results for the nine months ended September 2017 Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million The Bioscience Division sales grow
Sales of the Bioscience Division grow by +6.5%, increasing Grifols revenues to EUR 2,952 million
Results for the nine months ended September 2016 Sales of the Bioscience Division grow by +6.5%, increasing Grifols revenues to EUR 2,952 million over EUR 1,000 million and growth in the three divisions
CODE OF CONDUCT Business ethics and compliance
CODE OF CONDUCT Business ethics and compliance BUSINESS PARTNERS Index FRESENIUS KABI BUSINESS PARTNER CODE OF CONDUCT 3 ABOUT US 4 FRESENIUS KABI S BUSINESS: CARING FOR LIFE FRESENIUS KABI S CORE VALUES
Worldwide Supply and Demand of Plasma And Plasma- Derived Medicines
Original Article Worldwide Supply and Demand of Plasma And Plasma- Derived Medicines Patrick ROBERT, Ph.D. President of the Marketing Research Bureau, Inc., 284 Racebrook Road, USA,Phone: 001 203799-0298,
Five years as EMA Liaison at US FDA
Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines
Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective. IPFA Yogyakarta, March Louis Wong
Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective IPFA Yogyakarta, March 2017 Louis Wong Associate director, Plasma Initiative, Asia-Pacific Content Regulatory Expectations for Plasma-Derived
MODULE 11 Pharmacovigilance March 2017 POST-GRADUATE PROGRAMME IN PHARMACEUTICAL MEDICINE & MEDICINES DEVELOPMENT SCIENCES
MODULE 11 Pharmacovigilance 22-23 March 2017 POST-GRADUATE PROGRAMME IN PHARMACEUTICAL MEDICINE & MEDICINES DEVELOPMENT SCIENCES Robert VANDER STICHELE M.D., RUG and VUB, Senior Researcher, Health Technology
BIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
GUIDELINES FOR ISSUING AND RETURNING BLOOD COMPONENTS AND BLOOD PRODUCTS WITHIN A FACILITY
GUIDELINES FOR ISSUING AND RETURNING BLOOD COMPONENTS AND BLOOD PRODUCTS WITHIN A FACILITY 1. Policy Statement 1.1 A policy shall be in place to ensure traceability of all blood components and blood products
9/7/17. Implementing the ARK Immunoassay for Therapeutic Drug Monitoring of High-Dose Methotrexate. Disclosure. Learning Objectives
Implementing the ARK Immunoassay for Therapeutic Drug Monitoring of High-Dose Methotrexate Kristine R. Crews, PharmD, FCCP, BCPS St. Jude Children s Research Hospital September 14, 2017 Disclosure I declare
Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009
Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Committee Leadership Dr. Ellen Evans (Schering-Plough Research Institute), Chair Dr. Tom Kawabata (Pfizer Inc.), Vice
FUTURE MEANS CREATIVITY
START-UP & ACADEMICS THEORY & PRACTICE IN DRUG DEVELOPMENT 1 EARLY PHASE DRUG DEVELOPMENT COURSE MAY 9 TH 2017 - ANTWERP FUTURE MEANS CREATIVITY VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP,
Session 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
GUIDE FOR THE ASSESSMENT OF CLOTTING FACTOR CONCENTRATES
GUIDE FOR THE ASSESSMENT OF CLOTTING FACTOR CONCENTRATES 3 rd edition Prepared by Albert Farrugia, BSc, PhD for the World Federation of Hemophilia Published by the World Federation of Hemophilia (WFH)
SOP:10:QA:101:02:NIBT PAGE 1 of 11
SOP:10:QA:101:02:NIBT PAGE 1 of 11 Northern Ireland Blood Transfusion Service STANDARD OPERATING PROCEDURE (Operational Copy) Document Details Document Number: SOP:10:QA:101:02:NIBT No. of Appendices:
Paul Ashford Executive Director ICCBBA
Introduction to ISBT 128 Paul Ashford Executive Director ICCBBA ICCBBA ICCBBA enhances safety for patients by managing the ISBT 128 international information standard for use in transfusion and transplantation.
Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority
CHALLENGES AND OPPORTUNITIES IN COLD CHAIN: HEALTH CARE RELATED DRIVERS Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority AGENDA Integrating stakeholders
Global In-Vitro Diagnostic Market Report
Global In-Vitro Diagnostic Market Report ----------------------------------------------------- 2013 Executive Summary The process of performing a diagnostic test outside of a living organism in an artificial
Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions
First Half of 2017 Results Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions The Bioscience Division reports an exceptional increase in sales, which grow
Track and trace for access to safe medicines
Track and trace for access to safe medicines Every day millions of patients across the world depend on safe medication. Unfortunately, presence of falsified medication is a huge threat to patient safety,
Blood fractionation making the most of every drop. Pharmaceutical and Life Science Industries. siemens.com/pharma
Blood fractionation making the most of every drop Pharmaceutical and Life Science Industries siemens.com/pharma Proven Expertise The demand for blood plasma-based products is continuously increasing. But
PPTA Regulatory Workshop June 13, 2016
PPTA Regulatory Workshop June 13, 2016 DOROTY SCOTT Dr. Dorothy Scott is the Branch Chief for the Laboratory of Plasma Derivatives, in the Office of Blood Research and Review, CBER. Her group is responsible
A Common Data Model for Europe? Why? Which? How?
8 December 2017 EMA/550682/2017 A Common Data Model for Europe? Why? Which? How? 11-12 December 2017 European Medicines Agency, London, United Kingdom 30 Churchill Place Canary Wharf London E14 5EU United
Instructions on proper usage to ensure safe blood transfusion By Julie G. Jackson MT(ASCP)SBB
Instructions on proper usage to ensure safe blood transfusion By Julie G. Jackson MT(ASCP)SBB Revised 1/28/14 JJ Reviewed: MR Jones 1/28/14 Blood product storage is regulated by These regulations require
9th Open EIP Scientific Symposium. And. Final ABIRISK Open conference. Immunogenicity of Biopharmaceuticals. Draft Program November 2017
9th Open EIP Scientific Symposium And Final ABIRISK Open conference on Immunogenicity of Biopharmaceuticals Draft Program 13-16 November 2017 Altis Hotel Lisbon, Portugal Monday 13th November 2017 EIP
Global GS1 Healthcare Conference Lisbon, October 2012
22 nd Global GS1 Healthcare Conference GS1 Standards - a globally harmonized way to improve patient safety Join a few hundred key stakeholders at the 22 nd Global GS1 Healthcare Conference in Lisbon from
SPONSORSHIP MODELS GRADED SPONZORSHIP PACKAGES PLATINUM SPONSORSHIP (EXCLUSIVE) The value of the sponsorship model: 4,000 (VAT not included).
GRADED SPONZORSHIP PACKAGES SPONSORSHIP MODELS PLATINUM SPONSORSHIP (EXCLUSIVE) Complimentary full conference registration for three persons (access to all amenities) 9 m² of exhibition space at no charge
Excipient Albumin CSL Behring Human Serum Albumin
Excipient Albumin CSL Behring Human Serum Albumin For more information, contact CSL Behring USA: (610) 878-4000 1020 First Avenue King of Prussia, PA 19406-0901 Switzerland: +41 31 344 44 44 Wandorfstrasse
Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of Korea
Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of 2002-2003 Korea October 18, 2003 Ock-Joo Kim, M.D., Ph.D. General Secretary of KAIRB (Seoul, Korea) I. Foundation
European Institute of Public Administration (EIPA) O.L. Vrouweplein 22 NL-6211 HE Maastricht
INTRODUCTORY SEMINAR THE MUTUAL RECOGNITION OF DIPLOMAS AN INTRODUCTION TO THE REQUIREMENTS IMPOSED BY THE EU AND TO THE SYSTEMS ESTABLISHED TO FACILITATE THE WORK OF THE OFFICIALS Maastricht (NL), 12-13
Update on the IVDR. Sue Spencer
Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application
Regional Symposium on Climate Change
Regional Symposium on Climate Change The Abu Dhabi Global Environmental Data Initiative (AGEDI) in partnership with the UAE Ministry of Climate Change and Environment (MOCCAE) is proudly announcing that
SPECTRA OPTIA APHERESIS SYSTEM
Unlocking the Potential of Blood SPECTRA OPTIA APHERESIS SYSTEM Advancing therapeutic apheresis and cell collections to the next level of patient care ADVANCED TECHNOLOGY THAT GIVES YOU CHOICE AND PRECISION
MEDICAL DEVICES. Autopheresis-C SYSTEM. Virtually cell-free plasma
MEDICAL DEVICES Autopheresis-C SYSTEM Virtually cell-free plasma Your challenge is our concern: safely collect virtually cell-free plasma The Partner of Choice It s comprehensive. Autopheresis-C system.
BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective
BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective Alan E. Williams, Ph.D. Office of Blood Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration 15th International
European Epidemiological Forum
European Epidemiological Forum Observational Research and Pharmacoepidemiology in Europe: deeper insights to drive health research and discovery Amsterdam,The Netherlands Hyatt Place Amsterdam Airport
13 15 SEPTEMBER 2017 SERVING LABORATORY MANAGEMENT & DIOGNOSTIC NETWORKS GLOBALLY BARCELONA CONGRESS CENTRE, BARCELONA, SPAIN
13 15 SEPTEMBER 2017 BARCELONA CONGRESS CENTRE, BARCELONA, SPAIN SERVING LABORATORY MANAGEMENT & DIOGNOSTIC NETWORKS GLOBALLY www.medlabeurope.com medlabeurope@informa.com +34 518890041 INTRODUCTION It
System Biology and Immune Response
System Biology and Immune Response Fondation Mérieux Conference Centre Les Pensières Veyrier-du-Lac - France June 21-23, 2010 Steering Committee: Nicolas BURDIN Bruno GUY Michael KATZE Jacques LOUIS Ray
Exhibitor/Sponsor Prospectus
Exhibitor/Sponsor Prospectus GovTravels Expo Program: Lower Lobby Foyer, which is outside of the main meeting room, will serve as the GovTravels Resource Center. There and the right side of the Plaza Ballroom
MARKET SCOPING MISSION INFORMATION RAILWAY TECHNOLOGIES & SERVICES 27 NOVEMBER 1 DECEMBER 2017, JAPAN
EU Gateway Business Avenues eu-gateway.eu MARKET SCOPING MISSION INFORMATION RAILWAY TECHNOLOGIES & SERVICES 27 NOVEMBER 1 DECEMBER 2017, JAPAN Are you interested in applying for the Railway Technologies
Orange and Yellow Guides
PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING FIELD? Dr. Alison M.Beaney Regional Quality Assurance Specialist North-East England PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING
Coding Essentials for Laboratories 2017
Coding Essentials for Laboratories 2017 An Easy-to-Use Tool for Coding and Reimbursement Compliance Prepared and Published By: MedLearn Publishing A Division of Panacea Healthcare Solutions, Inc. 287 East
Subject: Invitation to the 12th Global Summit of National Ethics/Bioethics Committees
18/01/2018 Ref.: CL/4230 Subject: Invitation to the 12th Global Summit of National Ethics/Bioethics Committees Sir/Madam, I have the honour to invite your Government to nominate a participant to attend
Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD
Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.
INTERNAL AUDIT: PRINCIPLES, PROCEDURES AND PRACTICE IN THE EU MEMBER STATES Warsaw (PL), October 2007
Public Financial Management Seminar/Workshop INTERNAL AUDIT: PRINCIPLES, PROCEDURES AND PRACTICE IN THE EU MEMBER STATES Warsaw (PL), 11-12 October 2007 Seminar venue: Hyatt Regency Warsaw Hotel, Belwederska
GS1 Healthcare Japan. For the further involvement of Japanese HC Industry
GS1 Healthcare Japan For the further involvement Japanese HC Industry GS1 Healthcare Japan launched The first general assembly the GS1 Healthcare Japan took place on May 28, 2009. Around 100 attendees
Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404
Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this
Welcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae
Welcome to our 29 th Global GS1 Healthcare Conference Follow us on Twitter and tweet about the conference! @GS1Healthcare #GS1HCuae Welcome to the conference 29 th Global GS1 Healthcare Conference Dubai,
09/11/2015. Subject: Invitation for the 11th Global Summit of National Ethics/Bioethics Committees. Sir/Madam,
09/11/2015 Ref.: CL/4140 Subject: Invitation for the 11th Global Summit of National Ethics/Bioethics Committees Sir/Madam, I have the honour to invite your Government to nominate a participant to the 11th
Introductions and Perspectives on International Harmonization
Introductions and Perspectives on International Harmonization FDA/PQRI Conference on Evolving Product Quality September 17 th 2014 Mark Rosolowsky, PhD Vice President Global Regulatory Sciences CMC Bristol-Myers
AUSTRALIAN MEDICAL DEVICES GUIDANCE DOCUMENT NUMBER 5. The Declaration of Conformity
AUSTRALIAN MEDICAL DEVICES GUIDANCE DOCUMENT NUMBER 5 The Declaration of Conformity 30 October 2003 DISCLAIMER This document is provided for guidance only. It should not be relied upon to address every
Guide to Scientific and Regulatory Advice for GXP activities
Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
European Directorate for the Quality of Medicines & HealthCare (EDQM)
European Directorate for the Quality of Medicines & HealthCare (EDQM) INTERNATIONAL REGULATORY FORUM OF HUMAN CELL THERAPY AND GENE THERAPY PRODUCTS 16 MARCH 2016, OSAKA, JAPAN Dr Stephen J. Wicks Scientific
HCT/P Regulation vs 361 Products
HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public
Designing for Tomorrow
Register by credit card at http://dft.eventbrite.ca The City of Calgary and the proudly present the 14th Annual Stormwater Management Courses Designing for Tomorrow February 18 to 21 Carriage House Inn,
Creating Miracles in Life
Creating Miracles in Life November 2017 China Biologic Products Holdings, Inc. (NASDAQ: CBPO) Safe Harbor Statement 01 This presentation contains forward-looking statements, including statements about
COMMERCIALISM INTEGRITY STEWARDSHIP. Policy and procedure on flexitime system
Policy and procedure on flexitime system Policy and procedure on flexitime system Contents 1. Aim and purpose 1 2. General principle 2 3. Eligibility 2 4. Definitions 2 5. Procedure 2 6. Taking flexitime
Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
Food and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
GMO Technology Conference
GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October
COMMISSIONING IMMUNOGLOBULIN
COMMISSIONING IMMUNOGLOBULIN Advice to commissioners and commissioning bodies Dr. Henrietta E Ewart Consultant in Public Health Medicine, Solutions for Public Health Mr. Malcolm Qualie Head of Health Policy,
Good manufacturing practices
The rules governing medicinal products in the European Union Volume 4 Good manufacturing practices Medicinal products for human and veterinary use 1998 Edition EUROPEAN COMMISSION Directorate General III
GMP In-house Training
Your benefits: Customised to fit your company s requirements - cost-effective and flexible! GMP In-house Training for the Pharmaceutical, API and Medical Device Industry We offer practice-oriented GMP
Evaluation of the CompoMat G5 and CompoFlow and its potential for blood bank automation
32nd International Congress of the ISBT Cancun,, Mexico, July 7-12. 212 Evaluation of the CompoMat G5 and CompoFlow and its potential for blood bank automation Professor Dr. Christian Seidl, MD Vice Medical
Preparing for GMP audits
As a GMP licensed manufacturer, you should always be ready for an audit regulators can drop-in at any time. This White Paper provides some hints for preparing for a GMP audit. Whilst this White Paper focuses
OECD EXPERT WORKSHOP
OECD EXPERT WORKSHOP MEASURING ENVIRONMENTALLY ADJUSTED AGRICULTURAL TOTAL FACTOR PRODUCTIVITY (EATFP) AND ITS DETERMINANTS 14-15 December 2015 OECD Headquarters, Paris Draft Agenda (Final) For further
Production Assistance for Cellular Therapies PACT
Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs)
MARKET SCOPING MISSION INFORMATION ENVIRONMENT & WATER TECHNOLOGIES MAY 2018, JAPAN
EU Gateway Business Avenues eu-gateway.eu MARKET SCOPING MISSION INFORMATION ENVIRONMENT & WATER TECHNOLOGIES 21 25 MAY 2018, JAPAN Are you interested in applying for the Environment & Water Technologies
The 23 rd Autumn Introductory Course:
The 23 rd Autumn Introductory Course: Target the Heart of European Regulatory Affairs Prague, Czech Republic Sheraton Prague Charles Square hotel Zitna 561/8, Prague 13-17 November 2017 Monday 13 November
Summary of the Blood, Tissues and Cells Stakeholder Event. 20th September 2017
Ref. Ares(2017)5970353-06/12/2017 EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Directorate B - Health systems, medical products and innovation B4 Medical products: quality, safety,
EU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
Novel Technologies in Plasma Fractionation. Dieter Fassnacht
Novel Technologies in Plasma Fractionation Dieter Fassnacht Agenda Grifols Overview Grifols Engineering Innovations in - Pooling - Fractionation - Filling Developing new technologies to provide innovative
PACT. PACT Program. Production Assistance for Cellular Therapies
PACT Production Assistance for Cellular Therapies University of Wisconsin PACT-sponsored Workshop Developing Cellular Therapies: From Preclinical Safety To Clinical Evaluation Tuesday, April 09, 2013 Robert
Re: Paid Plasma in Canada and Canadian Blood Services Source Plasma Collection Plan
March 6, 2017 Open Letter to Provincial and Territorial Ministers of Health Dear Ministers: Re: Paid Plasma in Canada and Canadian Blood Services Source Plasma Collection Plan According to media reports,
SPONSORSHIP OPPORTUNITIES
SPONSORSHIP OPPORTUNITIES SPE WORKSHOP: Unlocking the Montney, Success Through Change 7-8 November 2017 Calgary Alberta, Canada HOTEL ARTS Workshop Website: www.spe.org/go/17aca6 About this Workshop As
Computer Validation - Introduction to Risk Management - The GAMP 5 Approach
Including implications of EU GMP Annex 11 computerised systems Computer Validation - Introduction to Risk Management - The GAMP 5 Approach Learn How to Plan, Implement and Document Effectively Computer
Bar coding in the Blood Bank
Bar coding in the Blood Bank for Ease, Speed + Accuracy Ann Mountain Wilson, TSO MUHC ICCBBA-GS1 International Meeting June 20, 2008 Bar coding in the blood bank Bar coded Blood components Non bar coded
FACTS. Federal Office for Safety in Health Care
FACTS Federal Office for Safety in Health Care 1 BASG / AGES MEA Federal Office for Safety in Health Care (BASG) and Austrian Medicines and Medical Devices Agency (AGES MEA) The Federal Office for Safety
Good Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
Draft of Programme of the International Seminar (Russia, Moscow, October 2015)
Draft of Programme of the International Seminar (Russia, Moscow, 15-16 October 2015) The Best Practice of Sustainable Urban Transport Systems Planning: from Realization of Large-Scale Infrastructure Projects
Septic Reactions from Apheresis Platelets What have we learned from 10 years of hemovigilance?
Septic Reactions from Apheresis Platelets What have we learned from 10 years of hemovigilance? Anne Eder, MD PhD Adjunct Associate Professor Georgetown University School of Medicine Chief, Blood Services